Aminaphtone, a drug used in the treatment of chronic venous insufficiency (CVI), showed a remarkable role in the modulation of several vasoactive factors, like endothelin-1 and adhesion molecules. The Authors analysed in vitro the effects of Aminaphtone on whole-genome gene expression and production of different inflammatory proteins.
In vitro, Aminaphtone was able to modulate the expression of inflammatory molecules relevant to the pathogenesis of several conditions in which the endothelial dysfunction is the main player and early event, like scleroderma, lung fibrosis, or atherosclerosis.
Salazar G, Bellocchi C, Todoerti K, Saporiti F, Piacentini L, Scorza R, Colombo GI. Gene expression profiling reveals novel protective effects of Aminaphtone on ECV304 endothelial cells. Eur J Pharmacol 2016;782:59-69. Go to PubMed